Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2/3 1Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 26INDUSTRY 4OTHER_GOV 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 13Gastrointestinal 9Breast 9Other hematologic neoplasm 7Thoracic 6Plasma cell 6Lymphoid 5Tumor-Agnostic 4Head & Neck 4Gynecologic 4CNS 4Dermatologic 2Sarcoma 1Other solid neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Standard of Care × Tumor-Agnostic × Clear all
NCT07005102 2026-06-05

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

AbbVie

Phase 2/3 Recruiting
854 enrolled
Tumor-Agnostic

Neoplasms

NCT06961188 2025-05-07

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
174 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03831633 2019-02-06

Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

VIFORFRANCE

Phase 4 Unknown
426 enrolled
Tumor-Agnostic

Neoplasms

NCT01558687 2014-02-04

Cilengitide Imaging Trial in Glioblastoma

Merck KGaA, Darmstadt, Germany

Phase 1 Terminated
1 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡